期刊文献+

非诺贝特上调血管内皮细胞一氧化氮合酶的表达(英文) 被引量:2

Fenofibrate increases endothelial nitric oxide synthase expression in bovine aortic endothelial cells
下载PDF
导出
摘要 目的观察PPARα激动剂非诺贝特对牛主动脉(BAECs)内皮细胞一氧化氮合酶(eNOS)活性和表达的影响。方法制备5-9代BAECs,加入不同浓度的非诺贝特(0,5,10,50,100μmol/L)后,用NOSAssayKit测定eNOS活性,RT-PCR法检测eNOSmRNA表达,Westernblot分析检测eNOS蛋白质表达。结果非诺贝特以浓度和时间依赖的方式增加eNOS活性,非诺贝特浓度10μmol/L以上时,明显增加eNOS活性。50μmol/L非诺贝特处理48h时eNOS活性最大(为对照组的232±047倍,P<001)。非诺贝特处理1h和12h不增加eNOS活性。RT-PCR分析表明,非诺贝特浓度大于5μmol/L以上时,明显增加eNOSmRNA水平,在非诺贝特浓度为50μmol/L时作用最大,为对照组的208±033倍(P<001)。此作用在6h时出现,持续到48h。Westernblot显示,非诺贝特处理48h,eNOS蛋白表达明显增加,在浓度为10,50和100μmol/L时,eNOS蛋白表达分别为对照组的180±045,270±042和220±032倍,均P<001。在非诺贝特处理12h后出现,持续到48h。结论PPARα激动剂非诺贝特增加BAECseNOS基因表达,提高eNOS活性及增加蛋白表达。 AIM: We hypothesize that peroxisome proliferator-activated receptor α(PPARα) agonists act directly on nitric oxide (NO) production in vascular endothelium. Thus, the purpose of this study is to investigate the effects of fenofibrate on endothelial NO synthase(eNOS) activity and its expression in cultured vascular endothelial cells. METHODS: Bovine aortic endothelial cells (BAECs) were treated with the PPARα activator fenofibrate. The eNOS activity and the expression of eNOS protein and its mRNA were determined. RESULTS: Our data show that fenofibrate increased eNOS activity in a dose-and time-dependent manner. At the concentration of 10 μmol/L or more, fenofibrate treatment caused a significant increase in eNOS activity. The maximal increase in eNOS activity(2 32±0 47 fold of the control) was observed with 50 μmol/L fenofibrate treatment for 48 h. Fenofibrate failed to increase eNOS activity at 1 and 12 h. RT-PCR analysis demonstrated that eNOS mRNA relative to β-actin mRNA significantly increased at concentrations of 5 μmol/L or more. It reached 2 08±0 33 fold of the control with 50 μmol/L fenofibrate. Significant increase in eNOS mRNA levels was observed after 6 h, and lasted for 48 h. The peak increase in eNOS mRNA levels(2 13±0 30 fold of the control, P <0 01) was observed with 50 μmol/L fenofibrate treatment for 12 h. Longer incubation of cells with 50 μmol/L fenofibrate caused no further increase. The treatment of BAECs with fenofibrate for 48 h demonstrated a concentration-dependent increase in eNOS protein levels as measured by Western blot analysis. Densitometric analysis indicated that there was a significant increase in eNOS to β-actin ratios after fenofibrate treatment at concentrations of 10,50 and 100 μmol/L(1 80±0 45, 2 70±0 42 and 2 20±0 32 fold of the control, respectively, P <0 01). The significant increase in eNOS protein levels was observed 12 h after treatment and lasted for 48 h. CONCLUSION: PPARα activator, fenofibrate, enhances endothelial NO production by directly upregulating eNOS expression and activity. [
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2004年第9期1621-1626,共6页 Chinese Journal of Pathophysiology
基金 theFoundationofCommitteeofScienceandTechnologyofGuangdongProvince(2KM04704S)
关键词 动脉硬化 内皮 一氧化氮合酶 非诺贝特 Arteriosclerosis Endothelium Nitric-oxide synthase Fenofibrate
  • 相关文献

参考文献2

二级参考文献11

  • 1Wang Z,Anal Chem,2000年,72卷,9期,2001页
  • 2Ishikawa M, Ouchi Y, Akishita M, et al. Immunocyto-chemical detection of parathyroid hormone - related protein in vascular endothelial cells[J]. Biochem Biophys Res Commun,1994, 199(2) :547- 551.
  • 3Ross R. Atherosclerosis- an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115 - 126.
  • 4Jones GT, Van Rij AM, Solomon C, et al. Endothelin- 1 is increased overlying atherosclerotic plaques in human arteries [J]. Atherosclerosis, 1996, 124(1) :25 - 35.
  • 5Marsen TA, Simonson MS, Dunn MJ. Thrombin induces the preproendothelin- 1 gene in endothelial cells by a protein tyrosine kinaselinked mechanism[J]. Circ Res, 1995, 76(6):987- 995.
  • 6Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease- fishing for a natural treatment [ J ].BMJ, 2004, 328(7430) :30- 35.
  • 7Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low- density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the diabetes atherosclerosis intervention study (DAIS) [ J ]. Circulation,2003, 107
  • 8Gervois P, Kleemann R, Pilon A, et al. Global suppression of IL- 6 - induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator- acivated receptor - alpha activator fenofibrate[ J ]. J Biol Chem,2004, 279
  • 9Ketrsten S, Desvergne B, Wahli W. Roles of PPARs in health and disease[J]. Nature, 2000, 405(6785) :421 - 424.
  • 10Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth- muscle cells is inhibited by PPARalpha but not by PPARgamma activators[J]. Nature, 1998, 393(6687):790 - 793.

共引文献9

同被引文献17

  • 1Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction[J]. J Clin Invest, 1997, 100(9): 2153- 2157.
  • 2Goya K, Sumitani S, Xu X, et al. Peroxisome proliferator-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells [J]. Arterioscler Thromb Vasc Biol, 2004, 24(4): 658-663.
  • 3Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferator- activated receptor gamma ligands increase release of nitric oxide from endothelial cells[J]. Arterioscler Thromb Vasc Biol, 2003, 23(1): 52-57.
  • 4Polikandriotis JA, Mazzella LJ, Rupnow HL, et al. Peroxisome proliferator- activated receptor γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator- activated receptor γ- dependent mechanisms[J]. Arterioscler Thromb Vasc Biol, 2005, 25(9): 1810-1816.
  • 5Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferators- activated receptors(PPARs) :tissue distribution of PPAR- alpha, - beta, and gamma in the adult rat[J]. Endocrinology, 1996, 137(1): 354-366.
  • 6Diabetes Atherosclerosis Intervention Study Inverstigators. Effect of fenofibrate on progression of coronary - artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study[J]. Lancet, 2001, 357(9260):905 - 910.
  • 7Sidhu JS, Kaposzta Z, Mark, s HS, et al. Effect of rosiglitazone on common carotid intima- media thickness progression in coronary artery disease patients without diabetes mellitus[J].Arterioscler Thromb Vasc Biol, 2004, 24(5): 930-934.
  • 8Cho DH, Choi Y J, Jo SA, et al. Nitric oxide production and regulation of endothelial nitric - oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator- activated receptor (PPAR)gamma- dependent and PPAR gamma- independent signaling pathways[J]. J Biol Chem, 2004, 279(4): 2499- 2506.
  • 9Ruotolo G, Ericson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)[J]. J Am Coll Cardiol, 1998, 32(6): 1648- 1656.
  • 10Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor- deficient mice[J]. Arterioscler Thromb Vase Biol, 2001, 21(3): 365- 371.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部